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Abstract
The spleen is an infrequent site for metastatic lesions, and solitary splenic metastases from squamous cell
carcinoma of the esophagus are very rare: only 4 cases have been reported thus far. These lesions are whitish
nodules that are macroscopically and radiologically similar to primary splenic lymphomas. We report a case of
metachronous splenic metastases from esophageal cancer and multiple splenic abscesses, which developed nine
months after apparently curative esophagectomy without adjuvant chemotherapy. The patient underwent
splenectomy dissection followed by adjuvant chemotherapy, but liver and skin metastases developed, and the
patient died 9 months later.
Keywords: splenic metastases, esophageal cancer, splenic abscesses
Background
Splenic metastases from solid malignancies generally
occur within a setting of extensive multiorgan involve-
ment. Over half of all patients with metastatic disease
involving five or more organs have lesions in the spleen
(often microscopic), and these patients represent 2-7%
of those who die from end-stage metastatic disease [1,2].
It is much less common to find the spleen as the sole
site of metastatic spread. In cases that have been
reported, the splenic metastases were synchronous or
metachronous lesions with patterns ranging from micro-
or macronodular to diffuse infiltration of both the white
and red pulp [3,4]. It is unclear why early splenic metas-
tases are so uncommon, but several of the organ’s fea-
tures are suspected to contribute to their rarity. They
include mechanical factors, such as the continuous nat-
ure of splenic blood flow, the rhythmic contraction of
the splenic capsule, the acute angle at which the splenic
artery branches from the celiac artery, and the absence
in the spleen of afferent lymphatic vessels. It has also
been suggested that the splenic microenvironment
exerts an inhibitory effect on metastases and that the
organ may produce a factor that inhibits the
proliferation of non-hematopoietic cells [4-6]. Radiologi-
cally, metastatic lesions of the spleen resemble primary
tumors involving this organ (e.g., lymphomas). Their dif-
ferential diagnosis is based essentially on fine-needle
aspiration cytology [FNAC] or surgical pathology.
Immunostaining can reveal the origin of the lesion:
epithelial (cytokeratins), melanocytic (S-100, HMB-45),
or lymphatic (B/T-cell line CD antigens) [7].
Thus far, 93 cases of solitary splenic metastases have
been reported in the literature. Most are secondary to
colorectal (20 cases), ovarian (18), or lung (10) cancers,
and adenocarcinoma primaries are more common than
epidermoid tumors [4,8]. Only four cases of solitary
metachronous metastases to the spleen in patients with
squamous cell carcinoma (SCC) of the oesophagus have
been documented so far [9-14] (Table 1). This report
describes a case of metachronous metastases from eso-
phageal SCC that were associated with multiple splenic
abscesses.
Case Presentation
A 59-year-old man was referred to the general surgery
department of our hospital for a one-month history of
progressive dysphagia for solids, which was not asso-
ciated with malnutrition or significant weight loss. The
patient had recently undergone esophagogastroduodeno-
scopy in another hospital, which revealed a bleeding,
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but no biopsy had been collected. The medical past his-
tory included COPD diagnosed in 1999 and a myocar-
dial infarction in 2002. The patient had smoked
approximately 25 cigarettes per day for several years.
Physical examination was unremarkable. Computed
tomography (CT) of the chest and abdomen revealed
stenosis involving a 5-cm segment of the middle third
of the esophagus with no other lesions in the thoracic
or abdominal organs. Barium studies disclosed a swel-
ling in the esophageal wall 7 cm above the cardia with
an ulcerative pattern, which reduced the diameter of the
lumen to 5 mm. An endoscopic biopsy of the oesopha-
geal mass demonstrated poorly differentiated (G3) squa-
mous cell carcinoma.
Mid-distal esophagectomy was performed with oeso-
phagogastric anastomosis and gastric tube reconstruc-
tion. Pathological examination of the surgical specimen
confirmed the biopsy diagnosis of poorly differentiated
(G3) SCC. The tumor, which measured 3 cm of length,
had infiltrated the oesophageal wall and the surrounding
paraesophageal fat. Surgical margins were tumor-free, as
the seven perigastric limph-nodes dissected (pT3 N0).
The postoperative period was quite unremarkable, and a
contrast enhanced x-ray obtained on the 9th POD
showed normal esophageal and gastric transit. On the
14th POD, the patient was discharged with an oncology
referral for routine medical follow-up.
Nine months after the operation, CT and esophago-
gastroduodenoscopy were repeated. The imaging study
revealed mild splenomegaly with multiple nonspecific
nodules within the organ (Figure 1). The patient was
virtually asymptomatic with the exception of a vague
sensation of mild discomfort in the left upper quadrant
of the abdomen. FNAC of the spleen revealed a pattern
of numerous inflammatory cells admixed with large cells
displaying immunohistochemical positivity for several
cytokeratins (Figure 2). The specimen was Gram stain-
negative. A bone-marrow biopsy was negative for meta-
static involvement. The diagnosis was isolated
Table 1 Details of all cases of splenic metastases from esophageal cancer reported in literature
Author Age
of
pt.
TNM Treatment Time to
onset of
spleen mts
Symptoms Treatment of
metastases
Findings Follow-up
Sanyal
et al
25 pT3N1Mx Transhiatal
esophagectomy
15 months Continuous, dull aching,
epigastric and left
hypocondrium pain radiating
to back, anorexia and weight
loss
Splenectomy,
distal
pancreasectomy,
splenic flexure
colon resection
Keratinizing
squamous cell
carcinoma
infiltrating the
pancreas
After 7
months
doing well
Vyas et
al
63 pT3N1Mx Transhiatal
esophagectomy
11 months Persistent pain and vague
fullness in the left
hypocondrium
Systemic
chemiotherapy
with cisplatin and
5FU
FNAB: metastatic
squamous cell
carcinoma
Death after
eleven
months
Hester 65 T3N2M1 Sistemic
chemiotherapy
Oxaliplatin and
capecitabine
9 months Left flank pain radiating to
the groin and ipovolemic
shock for spleen
spontaneous rupture
Splenic artery
embolization
Cavanna 50 T3N1M1 Systemic
chemiotherapy with
cisplatin and 5FU in
continuous infusione
(96 H)
synchronous Vague discomfort in upper
abdomen quadrant
Sistemic
chemiotherapy
FNAB: metastatic
squamous cell
carcinoma
Reduction
of the
spleen
lesion
about 50%
Kimura
et al
58 T3N0M0 Transhiatal
esophagectomy
6 months Vague discomfort in upper
abdomen quadrant
Splenic artery
embolization
followed by
splenectomy
Keratinizing
squamous cell
carcinoma
Figure 1 CT-scan showing the largest site of splenic
involvement: 8,5 × 7,6 cm.
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alterations.
The patient was referred to our centre for splenect-
omy, which was performed as a routine procedure to
role out, also, a spontaneous rupture of the spleen. On
12
th December 2007, the patient had transabdominal
total splenectomy with splenic and celiac artery lymph
node dissection.
The postoperative course was uneventful. On the 7
th
postoperative day, Doppler ultrasonography revealed
portal-tree patency with no signs of thrombosis. Ten
days later, the patient was discharged with a stable pla-
telet count (780,000/mm
3), Hb 10.9 g/dL, and a WBC
count of 16,500/mm
3.
Pathological examination of the spleen described mul-
tiple nodules containing medium to large-sized cells,
some of which were keratinized. The nodules were
mostly solid with areas of central necrosis (Figure 3).
The findings were consistent with metastases of SCC.
Thereafter, the patient was referred to the oncology
department of our hospital, where he received two 3-
day cycles (separated by a 3-week interval) of systemic
chemotherapy based on 5-fluorouracil (800 mg/day IV)
and cisplatin (20 mg/day). Three months after the sple-
nectomy, multiple liver metastases were seen on the CT
scan, and cutaneous metastases were also present. The
patient died 9 months later.
Discussion
The spleen is tenth on the list of sites for solid tumor
metastases [4-6,10]. Metachronous splenic metastasis
from oesophageal cancer is a very unusual finding: thus
far only four cases have been reported in the literature
[9-14]. Despite the organ’s high vascularity, the
incidence of splenic metastasis in patients with solid
tumors ranges from only 0.3% to 7.3%, and in over half
of these cases the splenic involvement is part of dissemi-
nated disease involving three or more organs [4]. Pri-
mary cancers of the breast, lung, colon and rectum,
ovary, and stomach are the ones most likely to metasta-
size to the spleen.
Isolated splenic metastases are very rare. Sileri et al.
recently reported a case of a single splenic metastasis
from colon cancer that appeared five years after surgery
[8]. Several anatomic, hemodynamic, and immunologic
hypotheses have been proposed to explain the rarity of
splenic metastases, but none of them are fully
convincing.
Consensus holds that metastases to the spleen are
hematogenous and may be a part of generalized blood-
borne dissemination. This assumption is largely based
on the hypothesis by Marymount and Gross, who con-
cluded that splenic metastases arise from circulating
cancer cells that arrive via the organ’s arterial blood
supply [15]. Back in 1929, Wolgom suggested that
tumor cells reaching the spleen might be destroyed by a
humoral substance produced in the organ itself, the so-
called splenic factor [7]. More recently, others have
claimed that the spleen’s resistance to metastases is
related to periodic contractions of the capsule, which
would keep the tumor cells in constant motion by for-
cing the blood from the sinusoids into the splenic veins
[4-6]. Others have suggested that metastatic tumor cells
arriving in the spleen would (like other foreign cells)
undergo phagocytosis in the Billroth cords by the
macrophages and tissue histiocytes [16].
The splenic lesions may be associated with vague non-
specific symptoms or with pain or discomfort (like that
reported by our patient). More frequently such condi-
tion are diagnosed incidentally on imaging studies per-
formed during routine follow-up. The increasing
Figure 2 Immunohistochemistry for pan-cytokeratin (KL-1 tag
with arrow) on fine-needle aspirate from the splenic lesion
highlights scattered positive cells (SABC method, 200×).
Figure 3 Spleen; surgical specimen: 17 × 11 × 6 cm, weight:
600 g.
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slice CT and MRI has led to the identification of an
increasing number of splenic metastases from different
types of solid tumors, which previously escaped detec-
tion [17].
Our experience confirms that locoregionally controlled
esophageal cancer can be associated with splenic metas-
tases. Our patient’s lesions were discovered during a
routine follow-up visit after a 9-month disease free
interval, and the patient had no clinical evidence of sys-
temic disease at the time. The splenic metastases
appeared as nonspecific lesions on abdominal CT and
were promptly subjected to FNAC. Space-occupying
lesions in this organ are more commonly related to
other causes, but when the patient has a history of
malignancy, the possibility that the splenic lesions are
metastatic must be ruled out.
Splenic metastases are not a widely discussed problem.
Because they are frequently associated with disseminated
metastases, their presence is usually considered a sign of
rapidly progressive disease that is no longer eligible for
curative treatment. Noteworthy exceptions are cases
occurring in patients with hematologic malignancies and
those in which the splenic involvement is limited to a
solitary lesion. The latter can sometimes be successfully
managed with splenectomy, particularly when lesion
onset occurs years after potentially curative surgical
resection of the primary tumor. Further studies are
necessary to define the prognostic impact of these
lesions and their potential relation to the original
histotype.
Conclusion
Esophageal carcinoma is a rare cause of splenic metas-
tases, and only four cases of isolated splenic meta-
chronous secondaries have been reported thus far
[3,9,10]. Given the unusual location of these lesions
and our limited understanding of their behavior, we
feel that splenectomy with en bloc lymph node dissec-
tion could help to stage the risk of further spread and
to clarify if a wide systemic involvement is already
present. Unfortunately a CT scan performed 3 months
after surgery revealed multiple metastases to the liver
and skin. The patient died 9 months later. Due to the
small number of cases that have been reported, the
role of adjuvant-combined modalities of treatment is
unclear. Further exploration of these approaches
might allow us to offer additional options for these
unfortunate patients.
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